Replies to post #2011 on The Rising Influence of Rising Affluence

[DewDiligence]

Correction: PFE’s 4Q10 year-over-year growth in emerging markets was 38% (not the 25% stated in #msg-59431783).

[DewDiligence]

Lipitor sales in emerging markets (from today’s WSJ):

http://online.wsj.com/article/SB10001424052702304543904577394263634380548.html

The company will continue to push the drug in emerging markets like China, where the company sees opportunities for multibillion dollar sales.

Indeed. Thanks to sales in emerging markets, Lipitor will continue to be a big-selling drug even though it is now off-patent nearly everywhere. My best guess is that Lipitor continues to sell $3B+ worldwide for years to come, which is a pretty big deal even for a company as big as PFE.